Phase 3
N=32
The Effects of Wellbutrin (Bupropion) on Residual and Cognitive Symptoms in SSRI-treated Depression
Depression · Major Depressive Disorder · Unipolar Depression
Bottom Line
View on ClinicalTrials.gov: NCT00125957 ↗Enrolled (actual)
32
Serious AEs
0.0%
Results posted
Aug 2014
Primary outcome: Primary: Montgomery-Asberg Depression Rating Scale (MADRS) — 22.0; 18.0; 12.0; 14.0 units on a scale — p=.04
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Wellbutrin (Drug); Placebo (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Mclean Hospital
- Primary completion
- Jan 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Montgomery-Asberg Depression Rating Scale (MADRS) |
22.0; 18.0; 12.0; 14.0 | .04 sig |
| PRIMARY Hamilton Depression Rating Scale (HAM-D) |
21.5; 14; 13.5; 14 | 0.09 |
Summary
Many people with depression are treated with a serotonin-specific reuptake inhibitor anti-depressant (SSRI) and feel 'better'. Although many people feel 'better', they do not feel completely 'well'. Often, individuals continue to complain of cognitive problems such as lack of attention, diminished motivation, and impaired problem-solving. This study looks at whether residual and cognitive symptoms of depression in individuals are affected by the addition of Wellbutrin (bupropion).
Eligibility Criteria
Inclusion Criteria
- Depression
- SSRI-treated
Exclusion Criteria
- Bipolar disorder
- Serotonin-norepinephrine reuptake inhibitor (SNRI) or bupropion treatment
- Treatment-resistant depression
- Seizure disorder
- Bulimia or anorexia nervosa
- Pregnancy
Data sourced from ClinicalTrials.gov (NCT00125957). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.